Recomendaciones modificadas para Celexa (citalopram bromhidrato) relacionadas con el riesgo potencial de ritmo cardiaco anormal con dosis altas. Esta actualización presenta información adicional relacionada con un […]

Safety AnnouncementAdditional Information for PatientsAdditional Information for Healthcare ProfessionalsData Summary  Safety Announcement [8-24-2011] The U.S. Food and Drug Administration (FDA) is informing healthcare professionals and patients […]

On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric […]

The FDA has issued new information about this safety issue, see the FDA Drug Safety Communication issued on 4-10-2012. This update is in follow-up to the […]

The FDA has issued new information about this safety issue, see the FDA Drug Safety Communication issued 04-10-2012. Safety AnnouncementAdditional Information for PatientsAdditional Information for Healthcare […]

FDA conducted a safety review and identified 14 cases of seizures linked to vitamin B6 deficiency in patients using drug products containing carbidopa/levodopa. The 14 cases […]

Esta actualización es a manera de seguimiento del Comunicado de la FDA sobre la seguridad de los medicamentos del 4 de febrero del 2012: Importante interacción […]

The FDA has issued new information about this safety issue, see the FDA Drug Safety Communication issued 5-7-2012. Safety AnnouncementAdditional Information for PatientsAdditional Information for Healthcare […]

Este informe actualizado se hace en seguimiento al Comunicado de la FDA sobre la seguridad de los medicamentos: Estudio de seguridad en curso de Revlimid (lenalidomida) […]